The Safety Rates Drug Report

Member Login
2004.Q1    2004.Q2    2004.Q3    2004.Q4    2005.Q1    2005.Q2    2005.Q3    2005.Q4    2006.Q1    2006.Q2    2006.Q3    2006.Q4    2007.Q1    2007.Q2    2007.Q3    2007.Q4    2008.Q1    2008.Q2    2008.Q3    2008.Q4    2009.Q1    2009.Q2    2009.Q3    2009.Q4    2010.Q1    2010.Q2    2010.Q3    2010.Q4    2011.Q1    2011.Q2    2011.Q3    2011.Q4    2012.Q1    2012.Q2    2012.Q3    2012.Q4    2013.Q1    2013.Q2    2013.Q3    2013.Q4    2014.Q1    2014.Q2    2014.Q3    2014.Q4    2015.Q1    2015.Q2    2015.Q3    2015.Q4    2016.Q1    2016.Q2    2016.Q3   

Drug     Injury     Quarter    

Person who experienced the adverse event (patient)

Event ID CASEID CASEVERSION I F COD EVENT DT MFR DT INIT FDA DT FDA DT REPT COD AUTH NUM MFR NUM MFR SNDR LIT REF AGE AGE COD AGE GRP GNDR COD E SUB WT WT COD REPT DT TO MFR OCCP COD REPORTER COUNTRY OCCR COUNTRY
80996983 8099698 3 F 20160530 20120911 20160711 EXP DE-CELGENEUS-062-21880-11081370 CELGENE KRONKE J, KUCHENBAUER F, KULL M, TELEANU V, BULLINGER L, BUNJES D. IKZF1 EXPRESSION IS A PROGNOSTIC MARKER IN NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH LENALIDOMIDE IN COMBINATION WITH INTENSIVE CHEMOTHERAPY: RESULTS OF THE GERMAN MYELOMA STUDY GROUP (DSMM).. 0.00 Y 0.00000 20160711 MD DE DE

Drug(s) used by person

Event ID CASEID DRUG SEQ ROLE COD DRUGNAME PROD AI VAL VBM ROUTE DOSE VBM CUM DOSE CHR CUM DOSE UNIT DECHAL RECHAL LOT NUM EXP DT NDA NUM DOSE AMT DOSE UNIT DOSE FORM DOSE FREQ
80996983 8099698 1 PS REVLIMID LENALIDOMIDE 1 Oral 25 MILLIGRAM U 21880 25 MG CAPSULES
80996983 8099698 2 SS ADRIAMYCIN DOXORUBICIN HYDROCHLORIDE 1 Unknown U 0 9 MG/M**2 UNKNOWN
80996983 8099698 3 SS ADRIAMYCIN DOXORUBICIN HYDROCHLORIDE 1 Unknown U 0 9 MG/M**2 UNKNOWN
80996983 8099698 4 SS DEXAMETHASONE. DEXAMETHASONE 1 Oral U 0 40 MG UNKNOWN
80996983 8099698 5 C Melphalan MELPHALAN 1 Unknown 0 200 MG/M**2 UNKNOWN
80996983 8099698 6 C HEPARIN HEPARIN SODIUM 1 Unknown 0 UNKNOWN
80996983 8099698 7 C PEGFILGRASTIM PEGFILGRASTIM 1 Unknown 40 MILLIGRAM 0 6 MG UNKNOWN

Indications of drugs used

Event ID CASEID INDI DRUG SEQ INDI PT
80996983 8099698 1 Plasma cell myeloma
80996983 8099698 2 Plasma cell myeloma
80996983 8099698 4 Plasma cell myeloma
80996983 8099698 5 Plasma cell myeloma
80996983 8099698 6 Thrombosis prophylaxis
80996983 8099698 7 Product used for unknown indication

Outcome of event

Event ID CASEID OUTC COD
80996983 8099698 DE
80996983 8099698 OT

Reactions reported

Event ID CASEID DRUG REC ACT PT
80996983 8099698 Adverse event
80996983 8099698 Anaemia
80996983 8099698 Arrhythmia
80996983 8099698 Atrial fibrillation
80996983 8099698 Back pain
80996983 8099698 Bone pain
80996983 8099698 Constipation
80996983 8099698 Cough
80996983 8099698 Death
80996983 8099698 Diarrhoea
80996983 8099698 Dry skin
80996983 8099698 Embolism venous
80996983 8099698 Fatigue
80996983 8099698 Febrile neutropenia
80996983 8099698 Graft versus host disease
80996983 8099698 Haematotoxicity
80996983 8099698 Headache
80996983 8099698 Herpes zoster
80996983 8099698 Hyperglycaemia
80996983 8099698 Infection
80996983 8099698 Influenza like illness
80996983 8099698 Leukopenia
80996983 8099698 Muscle spasms
80996983 8099698 Myocardial infarction
80996983 8099698 Nasopharyngitis
80996983 8099698 Nausea
80996983 8099698 Neutropenia
80996983 8099698 Peripheral sensory neuropathy
80996983 8099698 Plasma cell myeloma
80996983 8099698 Pneumonia
80996983 8099698 Polyneuropathy
80996983 8099698 Pruritus
80996983 8099698 Pulmonary embolism
80996983 8099698 Pyrexia
80996983 8099698 Rash
80996983 8099698 Respiratory tract infection
80996983 8099698 Second primary malignancy
80996983 8099698 Sepsis
80996983 8099698 Subclavian vein thrombosis
80996983 8099698 Thrombocytopenia
80996983 8099698 Thrombotic microangiopathy
80996983 8099698 Vomiting

Reporting Sources (this data is often not reported and may therefore be missing here)

no results found

Therapies reported

no results found